Nanocarrier-formulated anti-fibrotic peptides for cirrhosis - Fast Track SBIR

纳米载体配制的抗纤维化肽治疗肝硬化 - Fast Track SBIR

基本信息

  • 批准号:
    8102077
  • 负责人:
  • 金额:
    $ 43.23万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-04-01 至 2012-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This application pertains to the development of Medication for Hepatic Fibrosis. Established cirrhosis has a 10-year mortality of 34-66%, largely dependent on the cause of the cirrhosis; alcoholic cirrhosis has a worse prognosis than primary biliary cirrhosis and cirrhosis due to hepatitis. This application will be of interest to National institute of Alcohol Abuse and Alcoholism. Cirrhosis is long-term liver damage from the buildup of scar tissue (fibrosis) caused by infections, alcohol, excess fat, bile obstruction, and iron or cupper overload. Approximately 400,000 Americans suffer from liver cirrhosis. Cirrhosis affects millions of patients worldwide and remains an unresolved challenge for clinicians. Given the morbidity/mortality associated with this disease, there is an urgent need for translation of emerging anti-fibrotic molecules into effective therapies. Expediting clinical trials for compounds that have successfully undergone preclinical studies has the potential to make much needed medications available and reduce the need for liver transplantations. The scarring process in liver cirrhosis is mediated by Transforming Growth Factor 2 (TGF2) which is the most powerful fibrotic agent. Many known blockers of TGF2 are mostly peptides and proteins which cannot be easily developed onto drugs due to rapid degradation and kidney elimination once it reaches the blood stream. In this application, we propose to formulate three known TGF2 blocker peptides using advanced affinity-based nanocarrier technology. This will prevent rapid degradation and elimination and will maintain relatively constant concentration of active anti-fibrotic peptides in the blood, thus facilitating the transition of these peptide drugs from pre-clinical to clinical setting. We will synthesize nanocarriers appropriate for each of the anti-fibrotic peptides and we will determine affinity (1/Kd, where Kd is the dissociation constant) of the peptide for these nanocarriers. We will then formulate these peptides with appropriate nanocarriers and evaluate the in vivo pharmacokinetics in rats. Finally we will test the efficacy of formulated peptides in animal models of liver fibrosis. PUBLIC HEALTH RELEVANCE: Cirrhosis affects millions of patients worldwide and remains an unresolved challenge for clinicians. Cirrhosis is mediated by Transforming Growth Factor 2 (TGF2) and many known blockers of TGF2 action are peptides and proteins which cannot be easily developed onto drugs due to their rapid degradation and kidney elimination once they reach the blood stream. In this application, we propose to formulate known peptide blockers of TGF2 using advanced affinity-based nanocarrier technology that will prevent their rapid degradation and elimination and will maintain relatively constant concentration of anti-fibrotic peptides in the blood. This will facilitate the transition of these possible peptide drugs from pre-clinical to clinical settings.
描述(由申请人提供):本申请涉及肝纤维化药物的开发。已确诊的肝硬化的 10 年死亡率为 34-66%,很大程度上取决于肝硬化的病因;酒精性肝硬化的预后比原发性胆汁性肝硬化和肝炎性肝硬化差。国家酒精滥用和酒精中毒研究所将对此应用程序感兴趣。肝硬化是由感染、酒精、过量脂肪、胆汁阻塞以及铁或铜超载引起的疤痕组织堆积(纤维化)造成的长期肝损伤。大约有 40 万美国人患有肝硬化。肝硬化影响着全世界数百万患者,对于临床医生来说仍然是一个尚未解决的挑战。考虑到与这种疾病相关的发病率/死亡率,迫切需要将新兴的抗纤维化分子转化为有效的疗法。加快已成功进行临床前研究的化合物的临床试验有可能提供急需的药物并减少肝移植的需求。肝硬化的疤痕形成过程是由转化生长因子 2 (TGF2) 介导的,TGF2 是最强大的纤维化因子。许多已知的 TGF2 阻断剂大多是肽和蛋白质,由于一旦到达血流就会快速降解和肾脏消除,因此不能轻易开发成药物。在此应用中,我们建议使用先进的基于亲和力的纳米载体技术配制三种已知的 TGF2 阻断肽。这将防止快速降解和消除,并使血液中活性抗纤维化肽的浓度保持相对恒定,从而促进这些肽药物从临床前到临床的过渡。我们将合成适合每种抗纤维化肽的纳米载体,并确定肽与这些纳米载体的亲和力(1/Kd,其中Kd是解离常数)。然后我们将用适当的纳米载体配制这些肽并评估大鼠体内的药代动力学。最后,我们将测试配制的肽在肝纤维化动物模型中的功效。 公共卫生相关性:肝硬化影响着全世界数百万患者,对于临床医生来说仍然是一个尚未解决的挑战。肝硬化是由转化生长因子 2 (TGF2) 介导的,许多已知的 TGF2 作用阻断剂是肽和蛋白质,它们一旦进入血流就会迅速降解并被肾脏消除,因此不容易开发成药物。在此应用中,我们建议使用先进的基于亲和力的纳米载体技术配制已知的 TGF2 肽阻断剂,以防止其快速降解和消除,并维持血液中抗纤维化肽的相对恒定浓度。这将促进这些可能的肽药物从临床前到临床的过渡。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Elijah M. Bolotin其他文献

Compositions de supports a noyau hydrophobe pour l'administration d'agents therapeutiques, et procedes de preparation et d'utilisation
支持治疗剂施用、制备和利用过程的疏水性组合物
  • DOI:
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Gerardo M. Castillo;Elijah M. Bolotin
  • 通讯作者:
    Elijah M. Bolotin
Erratum to: Protected Graft Copolymer Excipient Leads to a Higher Acute Maximum Tolerated Dose and Extends Residence Time of Vasoactive Intestinal Peptide Significantly Better than Sterically Stabilized Micelles
  • DOI:
    10.1007/s11095-013-1061-0
  • 发表时间:
    2013-05-09
  • 期刊:
  • 影响因子:
    4.300
  • 作者:
    Sandra Reichstetter;Gerardo M. Castillo;Israel Rubinstein;Akiko Nishimoto-Ashfield;ManShun Lai;Cynthia C. Jones;Aryamitra Banerjee;Alex Lyubimov;Duane C. Bloedow;Alexei Bogdanov;Elijah M. Bolotin
  • 通讯作者:
    Elijah M. Bolotin

Elijah M. Bolotin的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Elijah M. Bolotin', 18)}}的其他基金

Vasoactive Intestinal Peptide for the treatment of Female Sexual Arousal Disorder
血管活性肠肽治疗女性性唤起障碍
  • 批准号:
    8638840
  • 财政年份:
    2014
  • 资助金额:
    $ 43.23万
  • 项目类别:
Nanocarrier formulated enzyme for the treatment of S. aureus infection
纳米载体配制的酶用于治疗金黄色葡萄球菌感染
  • 批准号:
    8468113
  • 财政年份:
    2012
  • 资助金额:
    $ 43.23万
  • 项目类别:
Nanocarrier formulated enzyme for the treatment of S. aureus infection
纳米载体配制的酶用于治疗金黄色葡萄球菌感染
  • 批准号:
    8392195
  • 财政年份:
    2012
  • 资助金额:
    $ 43.23万
  • 项目类别:
Vasoactive intestinal peptide for the treatment of psoriasis
血管活性肠肽治疗牛皮癣
  • 批准号:
    8248548
  • 财政年份:
    2012
  • 资助金额:
    $ 43.23万
  • 项目类别:
Vasoactive intestinal peptide for the treatment of psoriasis
血管活性肠肽治疗牛皮癣
  • 批准号:
    8540904
  • 财政年份:
    2012
  • 资助金额:
    $ 43.23万
  • 项目类别:
Nanocarrier-formulated anti-fibrotic peptides for cirrhosis - Fast Track SBIR
纳米载体配制的抗纤维化肽治疗肝硬化 - Fast Track SBIR
  • 批准号:
    7901175
  • 财政年份:
    2010
  • 资助金额:
    $ 43.23万
  • 项目类别:
Nanocarrier-formulated anti-fibrotic peptides for cirrhosis - Fast Track SBIR
纳米载体配制的抗纤维化肽治疗肝硬化 - Fast Track SBIR
  • 批准号:
    8097148
  • 财政年份:
    2010
  • 资助金额:
    $ 43.23万
  • 项目类别:
Outpatient treatment for portal hypertension
门静脉高压症的门诊治疗
  • 批准号:
    7801161
  • 财政年份:
    2010
  • 资助金额:
    $ 43.23万
  • 项目类别:
Nanocarrier with metal bridge for affinity based delivery of metal binding peptid
具有金属桥的纳米载体,用于基于亲和力的金属结合肽的递送
  • 批准号:
    7568232
  • 财政年份:
    2008
  • 资助金额:
    $ 43.23万
  • 项目类别:
Nanocarrier with metal bridge for affinity based delivery of metal binding peptid
具有金属桥的纳米载体,用于基于亲和力的金属结合肽的递送
  • 批准号:
    7475033
  • 财政年份:
    2008
  • 资助金额:
    $ 43.23万
  • 项目类别:

相似海外基金

Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
  • 批准号:
    23H01982
  • 财政年份:
    2023
  • 资助金额:
    $ 43.23万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
  • 批准号:
    23KJ0116
  • 财政年份:
    2023
  • 资助金额:
    $ 43.23万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
  • 批准号:
    10598276
  • 财政年份:
    2023
  • 资助金额:
    $ 43.23万
  • 项目类别:
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
  • 批准号:
    10682794
  • 财政年份:
    2023
  • 资助金额:
    $ 43.23万
  • 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233343
  • 财政年份:
    2023
  • 资助金额:
    $ 43.23万
  • 项目类别:
    Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233342
  • 财政年份:
    2023
  • 资助金额:
    $ 43.23万
  • 项目类别:
    Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
  • 批准号:
    479363
  • 财政年份:
    2023
  • 资助金额:
    $ 43.23万
  • 项目类别:
    Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
  • 批准号:
    10681989
  • 财政年份:
    2023
  • 资助金额:
    $ 43.23万
  • 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
  • 批准号:
    2237240
  • 财政年份:
    2023
  • 资助金额:
    $ 43.23万
  • 项目类别:
    Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
  • 批准号:
    2305592
  • 财政年份:
    2023
  • 资助金额:
    $ 43.23万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了